HCV-HIV co-infected patients: no longer a 'special' population?

Area of Science:

• Hepatology
• Infectious Diseases
• Virology

Background:

• Human immunodeficiency virus (HIV)/Hepatitis C virus (HCV) co-infection historically presented challenges due to rapid HCV progression and limited treatment options.
• Interferon-based therapies were less effective and posed drug interaction risks with HIV medications.
• The advent of oral direct-acting antivirals (DAAs) has transformed HCV treatment efficacy.

Purpose of the Study:

• To review the current landscape of HCV treatment in patients with HIV co-infection.
• To highlight persistent challenges and special considerations in the DAA era.
• To address ongoing issues such as disease burden, re-infection, drug interactions, and treatment duration.

Main Methods:

• Literature review of studies on HIV/HCV co-infection treatment.
• Analysis of outcomes with direct-acting antiviral (DAA) therapies.
• Evaluation of drug-drug interactions between HIV and HCV medications.
• Discussion of epidemiological trends in HCV re-infection.

Main Results:

• DAAs have significantly improved HCV treatment outcomes in HIV co-infected patients.
• High HCV disease burden persists, with notable rates of re-infection post-treatment.
• Careful management of drug-drug interactions between HIV and HCV DAAs is crucial.
• Optimal treatment durations for HCV in this population are still under investigation.

Conclusions:

• While DAAs have revolutionized HCV treatment, HIV/HCV co-infected patients require specialized management.
• Addressing ongoing HCV disease burden, re-infection risks, and drug interactions is paramount.
• Further research is needed to define optimal, potentially shorter, treatment regimens for HCV in co-infected individuals.